Zobrazeno 1 - 10
of 25
pro vyhledávání: '"M. A. Vernyuk"'
Autor:
A. A. Melnikova, F. M. Abbasbeyli, T. Yu. Mushkarina, M. A. Vernyuk, P. A. Zeynalova, L. Yu. Grivtsova, S. A. Ivanov, A. D. Kaprin
Publikováno v:
Онкогематология, Vol 19, Iss 3, Pp 92-98 (2024)
Background. The study of bone marrow involvement is a necessary step in disease staging, both in non-Hodgkin lymphomas and in the case of Hodgkin lymphoma (HL). The standard assessment of bone marrow lesion is carried out based on immunohistochemical
Externí odkaz:
https://doaj.org/article/360579da69d34047a33fa09780829d5c
Autor:
F. M. Abbasbeyli, A. A. Fedenko, P. A. Zeynalova, R. F. Zibirov, V. N. Grinevich, T. Yu. Mushkarina, A. A. Melnikova, M. A. Vernyuk, L. Yu. Grivtsova
Publikováno v:
Онкогематология, Vol 18, Iss 3, Pp 70-77 (2023)
Hodgkin’s lymphoma (HL) is a unique lymphoma of b-cell origin, the tumor cells of which have lost the expression of main b-cell antigens. The standard immunophenotype of the tumor substrate, according to immunohistochemical studies, is characterize
Externí odkaz:
https://doaj.org/article/39a21135b8514f22b01aa5f24ea5fe50
Autor:
F. M. Abbasbeyli, P. A. Zeynalova, M. A. Vernyuk, A. A. Fedenko, T. Yu. Mushkarina, A. A. Melnikova, V. Yu. Kovalskaya, L. Yu. Grivtsova
Publikováno v:
Онкогематология, Vol 18, Iss 3, Pp 84-91 (2023)
Background. Classical Hodgkin’s lymphoma is a B-cell lymphoproliferative disease, the tumor substrate of which is Berezovsky–Reed–Sternberg cells, characterized by CD30, PAX-5, CD15 expression and the absence of CD3, CD45. In some cases, tumor
Externí odkaz:
https://doaj.org/article/89dc140af91445169227191cbb59466b
Autor:
L. S. Khayrullina, M. A. Vernyuk, A. M. Chervontseva, I. V. Cherkashina, E. E. Gushchina, A. A. Fedenko
Publikováno v:
Онкогематология, Vol 17, Iss 3, Pp 114-118 (2022)
Classical Hodgkin's lymphoma is one of the most treatable lymphoproliferative diseases with current chemotherapy regimens. The 5-year overall survival rate among patients after initial chemotherapy reaches 95 %, however, despite the significant succe
Externí odkaz:
https://doaj.org/article/3be6bb94a6c44243823243fe4354013a
Autor:
A. A. Mamedova, N. E. Mochkin, V. O. Sarzhevskiy, E. A. Demina, V. S. Bogatyrev, A. A. Spornik, A. A. Samoylova, A. A. Rukavitsin, E. G. Smirnova, A. E. Bannikova, V. Ya. Melnichenko, N. B. Mikhaylova, E. S. Borzenkova, L. V. Stelmakh, Yu. R. Zalyalov, A. A. Semenova, G. S. Tumyan, M. A. Danilova, O. A. Konova, N. A. Falaleeva, A. Yu. Terekhova, M. A. Vernyuk, A. M. Chervontseva, L. S. Khayrullina, A. A. Maslov, I. B. Lysenko, Yu. A. Alekseeva, E. S. Pavlyuchenko, A. A. Mirsaitov, A. A. Zverkova, I. V. Ishmatova, S. A. Volchenkov, M. S. Motalkina, I. S. Zyuzgin
Publikováno v:
Онкогематология, Vol 17, Iss 3, Pp 40-47 (2022)
Aim. To study the efficacy and safety of combined immunochemotherapy according to the DHAp protocol + nivolumab in patients with refractory/relapsed classical Hodgkin's lymphoma before autologous hematopoietic stem cell transplantation.Materials and
Externí odkaz:
https://doaj.org/article/61dd8e7c89fc477eb1ba03f4c408b04b
Autor:
M. A. Vernyuk, A. M. Chervontseva, I. V. Cherkashina, E. E. Gushchina, L. S. Khayrullina, A. A. Fedenko
Publikováno v:
Онкогематология, Vol 17, Iss 2, Pp 14-22 (2022)
Follicular lymphoma (FL) refers to indolent mature B-cell lymphomas and, despite the recurrent course, is generally characterized by a favorable prognosis with long-term overall survival. However, in about 20 %, the disease has an aggressive course w
Externí odkaz:
https://doaj.org/article/1150c022b3764ace9c3b3439842254b8
Autor:
I. V. Cherkashina, M. A. Vernyuk, A. M. Chervontseva, E. E. Gushchina, L. S. Khayrullina, V. V. Lunin, P. A. Zeynalova, A. A. Fedenko
Publikováno v:
Онкогематология, Vol 16, Iss 2, Pp 10-20 (2021)
Primary lymphoma of the central nervous system (PLCNS) is a rare form of extranodal lymphoma characterized by an aggressive course. In recent decades, the treatment of this disease has undergone significant changes. Modern treatment of PLCNS consists
Externí odkaz:
https://doaj.org/article/57532362c7734f44a918aef7129a05f6
Autor:
N. V. Zhukov, A. L. Uss, N. F. Milanovich, V. V. Ptushkin, B. V. Afanasiev, N. B. Mikhaylova, V. B. Larionova, Ye. A. Demina, N. G. Tyurina, M. A. Vernyuk, Ye. Ye. Karamanesht, A. G. Rumyantsev
Publikováno v:
Онкогематология, Vol 9, Iss 3, Pp 32-40 (2015)
The influence of previous antitumor therapy the efficacy and tolerability of high-dose chemotherapy with autologous hematopoietic progenitor cells transplantation (HCST) in 369 patients with Hodgkin, s lymphoma in the clinics of Russia and CIS countr
Externí odkaz:
https://doaj.org/article/9e6e7f17fa354ebf9f9c5a8190d253ae
Autor:
N. V. Zhukov, A. L. Uss, N. F. Milanovich, V. V. Ptushkin, B. V. Afanasiev, N. B. Mikhaylova, V. B. Larionova, E. A. Demina, N. G. Tyurina, M. A. Vernyuk, E. E. Karamanesht, A. G. Rumyantsev
Publikováno v:
Онкогематология, Vol 9, Iss 2, Pp 37-44 (2014)
Autologous hematopoietic stem cell transplantation (HSCT) is the standard treatment for patients with relapsed and primary refractoryHodgkin's lymphoma (HL). According to current recommendations HSCT must be performed in first relapse or after regist
Externí odkaz:
https://doaj.org/article/a6a5819cace74f079c937d2e1c275049
Publikováno v:
Онкогематология, Vol 8, Iss 4, Pp 18-23 (2014)
Due to the relative low incidence of primary mediastinal B-large cell lymphoma (PM BLCL) optimal approaches to its treatment is still not well developed. Possibility to improve PM BLCL clinical outcomes by intensifying induction chemotherapy (CT) and
Externí odkaz:
https://doaj.org/article/92ced134509c4f979192382fbc36a309